Standout Papers
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy (2017)
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study (2011)
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 (2019)
Immediate Impact
1 by Nobel laureates 5 from Science/Nature 79 standout
Citing Papers
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Analysis of Breast Cancer Mortality in the US—1975 to 2019
2024 Standout
Works of Han Koh being referenced
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
2017 Standout
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
2011 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Han Koh | 1883 | 2178 | 507 | 836 | 25 | 2.7k | |
| C. Giorgetti | 2144 | 2077 | 542 | 874 | 33 | 2.9k | |
| Eric Gauthier | 2492 | 2337 | 632 | 889 | 41 | 3.0k | |
| Nawel Bourayou | 2026 | 1797 | 536 | 723 | 23 | 2.3k | |
| Kathy Puyana Theall | 2049 | 1828 | 537 | 787 | 26 | 2.3k | |
| Susana Barriga | 3179 | 2770 | 882 | 1194 | 25 | 3.5k | |
| Olga Burdaeva | 1630 | 1563 | 445 | 621 | 27 | 2.0k | |
| Meena Okera | 1678 | 1488 | 470 | 617 | 32 | 2.0k | |
| Martin Frenzel | 3512 | 3102 | 957 | 1269 | 26 | 3.9k | |
| Janice M. Walshe | 2041 | 2422 | 497 | 1119 | 69 | 3.3k | |
| Katarína Petráková | 1351 | 2074 | 286 | 962 | 64 | 2.7k |
All Works
Loading papers...